Inclusion Criteria:

• 18 years of age
• Has end stage renal disease (ESRD) and is to receive a kidney transplant from a DD to whom he/she has a positive T or B cell crossmatch >200 at the time of transplant and DSA demonstrated by solid phase assays.
• Willing to comply with the protocol
• Females of child-bearing potential must have a negative pregnancy test (serum β-HCG) and sexually active females must agree to use a reliable and medically approved method of contraception
• Willing and able to give written informed consent
• Vaccinated against Neisseria meningitides (quadrivalent vaccine), Pneumococcus and H. influenzae at least two weeks prior to beginning desensitization

Exclusion Criteria:

• Unstable cardiovascular condition
• Previous splenectomy
• Active bacterial or other infection which is clinically significant in the opinion of the investigator
• Known or suspected hereditary complement deficiency
• Participation in any other investigational drug study or was exposed to an investigational drug or device within 30 days of randomization
• Pregnant, breast-feeding, or intending to conceive during the course of the study, including a one month follow-up period after drug discontinuation
• Known hypersensitivity to the treatment drug or any of its excipients
• History of illicit drug use or alcohol abuse within the previous year
• History of meningococcal disease
• Medical condition that, in the opinion of the investigator, might interfere with the patient's participation in the study, pose an added risk for the patient, or confound the assessment of the patient (e.g. severe cardiovascular or pulmonary disease)